Zevra Therapeutics/$ZVRA
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Zevra Therapeutics
Zevra Therapeutics Inc is a commercial-stage company with a late-stage pipeline committed to bringing life-changing therapeutics to people living with rare diseases. The Company is focused on expanding patient access, progressing its pipeline toward key milestones, and delivering meaningful outcomes for patients with unmet needs. The commercialization of its product, marketed in the United States for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disease, provides a corporate foundation and demonstrates its ability to advance therapies from development to market.
- Ticker
- $ZVRA
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 61
- Headquarters
- Boston, United States
- Website
- www.zevra.com
ZVRA Metrics
BasicAdvanced
$583M
11.12
$0.88
0.95
-
Price and volume
Market cap
$583M
Beta
0.95
52-week high
$15.04
52-week low
$8.01
Average daily volume
874K
Financial strength
Current ratio
5.167
Quick ratio
5.018
Long term debt to equity
0.004
Total debt to equity
0.007
Interest coverage (TTM)
6.84%
Profitability
EBITDA (TTM)
40.553
Gross margin (TTM)
95.46%
Net profit margin (TTM)
42.82%
Operating margin (TTM)
28.71%
Effective tax rate (TTM)
15.91%
Revenue per employee (TTM)
$2,230,000
Management effectiveness
Return on assets (TTM)
8.74%
Return on equity (TTM)
34.80%
Valuation
Price to earnings (TTM)
11.124
Price to revenue (TTM)
4.144
Price to book
2.67
Price to tangible book (TTM)
2.81
Price to free cash flow (TTM)
17.285
Free cash flow yield (TTM)
5.79%
Free cash flow per share (TTM)
0.568
Growth
Revenue change (TTM)
119.40%
Earnings per share change (TTM)
-1,355.30%
3-year revenue growth (CAGR)
101.86%
3-year earnings per share growth (CAGR)
25.57%
10-year earnings per share growth (CAGR)
-34.24%
What the Analysts think about ZVRA
Analyst ratings (Buy, Hold, Sell) for Zevra Therapeutics stock.
Analyst projections of the future price of Zevra Therapeutics stock.
Bulls say / Bears say
MIPLYFFA is gaining commercial traction: Q2 2026 net sales rose 40% year on year to $30.2 million, helping lift total revenue 53% to $39.7 million. Operating expenses also fell year on year, supporting a path to stronger underlying profitability. (Zevra Therapeutics)
The balance sheet gives Zevra room to fund growth without an immediate financing need: it held $260.2 million in cash and investments at Q2 end and had repaid its term loan. Management said those resources were sufficient to execute its plans independently of capital markets. (Zevra Therapeutics, Zevra Therapeutics)
The US opportunity could extend beyond today’s diagnosed market: management estimates 350–900 potential NPC patients, compared with roughly 300–350 currently diagnosed. Zevra had received 184 MIPLYFFA prescription forms by the end of Q2, leaving scope for growth if diagnosis efforts reach more patients. (Investing.com, Zevra Therapeutics)
European expansion is uncertain after the EMA’s CHMP issued a negative opinion, saying efficacy had not been sufficiently demonstrated. Zevra has sought re-examination, but approval and the timing of any European sales remain unresolved. (Medscape, Zevra Therapeutics)
Revenue is concentrated in MIPLYFFA: it generated $30.2 million of Q2’s $39.7 million total, while OLPRUVA contributed only $0.2 million. Expanded-access reimbursements are less predictable, leaving results reliant on continued MIPLYFFA sales growth. (Zevra Therapeutics, StockNow)
The celiprolol Phase 3 trial for vascular Ehlers-Danlos syndrome has an uncertain timeline: by Q2 end, only three confirmed events had occurred, against 28 needed for interim analysis, and 66 of 150 planned patients were enrolled. A slow event rate could delay the programme’s next meaningful readout. (Zevra Therapeutics)
Data summarised monthly by Lightyear AI. Last updated on 27 Oct 2026.
ZVRA Financial Performance
Revenues and expenses
ZVRA Earnings Performance
Company profitability
Upcoming events
No upcoming events
ZVRA News
AllArticlesVideos
Funds containing ZVRA
Fund name | Fund size | $ZVRA weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.1B | 0.04% |
iShares Nasdaq US Biotechnology£BTEK | $1.1B | 0.04% |
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.02% |
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.02% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.